Spruce Biosciences, Inc. - SPRB Total Company Value-to-Revenue Ratio

Spruce Biosciences (SPRB) - corporate logo

The prospects for Spruce Biosciences (SPRB) depend on the outcomes of late-stage trials and the approved pricing for rare pathology therapies. The enterprise value-to-sales multiple demonstrates valuation volatility, where the 0.00 level serves as a critical benchmark. The company's strategy relies on expanding the tildacerfont portfolio to capture market share, although the lack of commercial products creates a temporary capital deficit.

SPRB Spruce Biosciences, Inc.: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

SPRB (Spruce Biosciences, Inc.): analytical breakdowns and indicator data

Initial company analysis:Spruce Biosciences, Inc. SPRB
Original product of sprucebiosciences.com

A conservative approach requires valuing Spruce Biosciences (SPRB) through the lens of actual cash generation, excluding the impact of leverage. This EV-to-sales ratio compares the total enterprise value with revenue, allowing for an assessment of the premium paid for Tildacerfont's patent protection and exclusive clinic access, which is critical for understanding the investment profile of this pharmaceutical ecosystem.

Direct competitors

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|ETNB: EV/Sales Multiple|AGIO - Total Company Value-to-Revenue Ratio|Company Value to Revenue GPCR|Enterprise Value-to-Revenue Multiple MiMedx MDXG|Enterprise Value-to-Revenue Ratio Rezolute Corp (RZLT)|Company Value to Revenue Lexicon Corp LXRX|Enterprise Value-to-Revenue Ratio MBX Biosciences, Inc. MBX|EV/Sales Multiple altimmune.com ALT|AARD - Enterprise Value-to-Revenue Ratio|Sagimet - Enterprise Value-to-Revenue Coefficient|BioAge Labs Inc. (BIOA) - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume BMEA (Biomea Fusion, Inc.)|QNCX (quincetx.com) - EV/Sales Multiple|GUTS: Business Value to Revenue|Enterprise Value-to-Revenue Ratio vtvtherapeutics.com (VTVT)|ATPC (Agape ATP) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Pluristem Therapeutics PLUR|SYBX: Company Value to Revenue Ratio|lipocine.com - EV/Sales Multiple|Enterprise Value to Sales Volume MTNB|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)